Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962109 | 1.00 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL14962111 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL3895214 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL634530 | 0.82 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL635072 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3895066 | 0.79 | SLC6A2 (0.75) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL636090 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL636087 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL636089 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL636088 | 0.78 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1002794-B1 | 4-¬(Aryl)(aryloxy)methyl piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES FABRICA ESPANOLA DE PRODU (ES) | 2009-02-04 | — | — | EP | claimed |
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | FAES FARMA, S.A. (ES) | 2013-05-23 | — | — | US | disclosed |
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | FAES FARMA, S.A. (ES) | 2013-05-23 | — | — | US | disclosed |
| WO-2011147780-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMILOYD PATHOLOGIES | FAES FARMA, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131079-A1 | FLUFENOXINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF AMYLOID PATHOLOGIES | APP, MAPT, PSEN1 | SLC6A2 173/4885SLC6A4 325/4885SLC6A3 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.